H3A.Clinical.and.Population.Dataset.2021.v1
The H3A Diabetes Study: A multi-centre study of the prevalence and environmental and genetic determinants of type 2 diabetes in sub-Saharan Africa. (Field Data collection 2015-2018)
Name | Country code |
---|---|
South Africa | ZA |
Objective
The objective of the study is to assess the burden and the spectrum of environmental and genetic determinants of T2D and selected associated microvascular complications in SSA.
Methods
A multi-national study integrating epidemiological and genomic techniques designed as case-series and population based cross-sectional surveys at 10 sites in 7 countries spanning west, east and southern Africa. Up to 6000 cases of T2D from health facilities and 6000 population based controls will be recruited. This design makes it possible to efficiently draw cases of T2D from health facilities and align them to controls from an appropriate base population while providing an opportunity to estimate prevalence from the survey component of the study. The integrated approach provides a framework for assessing burden, spectrum, and environmental and genetic risk factors for T2D and associated clinical complications.
Includes data on:Socio-demographic, biophysical and anthropometric, biochemical factors as well as fundus image grading.
The unit of analysis is the human individual. Each record corresponds to an individual.
V1.0.0
Topic | Vocabulary | URI |
---|---|---|
Diabetes Mellitus, Type 2 | Africa Health Research Institute | www.ahri.org |
Cameroon, Guinea, Malawi, Nigeria, South Africa, Tanzania, Uganda
The population in both the survey and clinic arms of the study was of self-identified black Africans, 18 years or older and resident in their respective localities. The inclusion and exclusion criteria are in the table below.
Inclusion and Exclusion criteria
Clinic Arm
Inclusion
Age=>25 years. Clinically diagnosed T2D based on data extracted from patient medical records according to current ADA and WHO definitions.
Fasting plasma glucose (FPG) =>7.0mmol/ (=>126mg/dl) OR o Two-hours post-load glucose (2h-PG) =>11.1 mmol/l (=>200mg/dl) OR o Symptoms of diabetes and random plasma glucose => 11.1 mmol/l (=200mg/dl) OR o On oral or insulin treatment for diabetes. Individual of African origin (Black) Signed informed consent.
Exclusion
· Pregnant women - can participate six months after childbirth
· Diabetes classified other than T2D or doubt as to classification
· Living outside the geographical sampling frame for the relevant site
· Self-defined ethnic group regarded as other than African (Black)
· Unable to give informed consent
Survey Arm
Inclusion
Resident in the relevant geographical sampling frame
Age=>18 years · Individual of African origin (Black)
Signed informed consent
Exclusion
· Pregnant women - can participate six months after childbirth
· Resident outside the relevant geographical sampling frame
· Self-defined ethnic group regarded as other than African (Black)
· Unable to give informed consent
Name | Affiliation |
---|---|
Motala Ayesha† | Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban |
Adebamowo Clement | Institute of Human Virology, Abuja |
Balde Naby | CHU Donka, University of Conakry |
Kaleebu Pontiano | MRC/UVRI Unit Uganda |
Kapiga Saidi | Mwanza Intervention Trials Unit/NIMR Tanzania |
Levitt Naomi | Faculty of Health Sciences, University of Cape Town |
Mayige Mary | National Institute for Medical Research, Dar es Salaam |
McCarthy Mark | Wellcome Trust Centre for Human Genetics; MRC Centre for Global Health Genomics, Oxford University |
Nyirenda Moffat , Heyderman Robert | Malawi-Liverpool-Wellcome Trust Unit, Blantyre |
Oli John | University of Nigeria Teaching Hospital, Enugu |
Rotimi Charles | National Human Genome Research Institute, National Institutes of Health |
Sandhu Manjinder | University of Cambridge |
Sobngwi Eugene | University of Yaoundé 1 |
Smeeth Liam | London School of Hygiene and Tropical Medicine |
Kenneth Ekoru | US National Institutes of Health |
† Lead Principal investigator |
Name |
---|
Africa Health Research Institute |
Name | Role |
---|---|
Wellcome Trust | Funder |
Name | Affiliation | Role |
---|---|---|
Kenneth Ekoru | US National Institutes of Health | Programme Manager |
Nelisiwe Mtshali | Africa Health Research Institute | Data manager |
Teniola Akeredolu | Institute of Human Virology, Abuja | Study coordinator |
Jean Claude Katte | University of Yaoundé 1 | Study coordinator |
Gibson Kagaruki | National Institute for Medical Research, Dar es Salaam | Study coordinator |
Nonhlanhla Nombula | Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban | Study coordinator |
Christian Okafor | University of Nigeria Teaching Hospital, Enugu | Study coordinator |
Mamadou Cherif Diallo | CHU Donka, University of Conakry | Study coordinator |
Odala Chithodwe | Malawi-Liverpool-Wellcome Trust Unit, Blantyre | Study coordinator |
Asungushe Kayombo | Mwanza Intervention Trials Unit/NIMR Tanzania | Study coordinator |
Clara Wekesa | MRC/UVRI Unit Uganda | Study coordinator |
Linda Visser | Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban | Retinopathy grading lead |
Sureyah Nassimbwa | MRC/UVRI Unit Uganda | Laboratory coordinator |
Peter Hughes | MRC/UVRI Unit Uganda | Laboratory head |
Mia Crampin | Malawi-Liverpool-Wellcome Trust Unit, Blantyre | Site Co-PI |
Bonginhlanhla Ernest Mbambo | Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban | Finance officer |
Dickman Gareta | Africa Health Research Institute | Head:Research Data Management |
Keabetswe Dikgale | Africa Health Research Institute | Research Data Manager |
T2D cases were recruited purposively selected from health facilities within the geographical location of study centres using patient registers as sampling frames. Surveys were conducted in the catchment areas of the selected health facilities using a two-stage cluster sampling design involving predefined geographical areas such as administrative units and households. Listings of administrative units and households were obtained from each country's National Statistics Office or equivalent agency, or generated with the help of a local leader of the area to provide a sampling frame.
Start | End |
---|---|
2015-01-01 | 2018-12-04 |
The representative of the Receiving Organization agrees to comply with the following conditions:
Motala, A., Adebamowo, C., Balde, N., Kaleebu, P., Kapiga, S., Levitt, N., Mayige, M., McCarthy, M., Nyirenda, M., Heyderman, R., Oli, J., Rotimi, C., Sandhu, M., Sobngwi, E., Smeeth, L., & Ekoru, K. (2021). The H3A Diabetes Study: A multi-centre study of the prevalence and environmental and genetic determinants of type 2 diabetes in sub-Saharan Africa. (Field Data collection 2015-2018) [Data set]. Africa Health Research Institute (AHRI). https://doi.org/10.23664/H3A.CLINICAL.AND.POPULATION.DATASET.2021.VERSION.1
DDI.H3A.Clinical.and.Population.Dataset.2021.v1
Name |
---|
Africa Health Research Institute |